| 丹红注射液治疗冠心病心绞痛的系统评价再评价 |
| |
| 引用本文： | 刘书君,徐嘉敏,谢建辉,李倩,杨小波.丹红注射液治疗冠心病心绞痛的系统评价再评价[J].中国医院药学杂志,2022,42(8):854-859. |
| |
| 作者姓名： | 刘书君 徐嘉敏 谢建辉 李倩 杨小波 |
| |
| 作者单位： | 1. 广州中医药大学第二临床医学院, 广东 广州 510405;2. 广州中医药大学第二附属医院, 省部共建中医湿证国家重点实验室, 广东 广州 510120;3. 广东省中医证候临床研究重点实验室, 广东 广州 510120 |
| |
| 基金项目： | 国家自然科学基金面上项目（编号:81673845）；广东省重点研发计划项目（编号:2020B1111100010） |
| |
| 摘 要： | 目的:基于AMSTAR2量表和GRADE系统对丹红注射液治疗冠心病心绞痛的系统评价进行再评价。方法:计算机检索CBM、知网、万方、维普、PubMed、The Cochrane Library、Embase及Web of Science数据库，收集丹红注射液治疗冠心病心绞痛相关的系统评价或Meta分析。筛选及提取文献信息后，采用AMSTAR2量表和GRADE系统对纳入研究的方法学质量和证据质量进行评价。结果:最终纳入13篇文献，AMSTAR2评价结果均为极低级。GRADE系统评级显示，6个结局指标为中级证据、17个为低级证据、26个极低级证据。结论:目前丹红注射液治疗冠心病心绞痛的系统评价方法学质量和证据质量较低，未来应开展更高质量的临床研究，提高二次研究的方法学质量。
|
| 关 键 词： | 丹红注射液 心绞痛 系统评价再评价 AMSTAR2质量评价 GRADE系统 |
| 收稿时间： | 2021-08-17 |
Danhong Injection treatment for angina pectoris:an overview of systematic reviews |
| |
| LIU Shu-jun,XU Jia-min,XIE Jian-hui,LI Qian,YANG Xiao-bo.Danhong Injection treatment for angina pectoris:an overview of systematic reviews[J].Chinese Journal of Hospital Pharmacy,2022,42(8):854-859. |
| |
| Authors: | LIU Shu-jun XU Jia-min XIE Jian-hui LI Qian YANG Xiao-bo |
| |
| Affiliation: | 1. School of Second Clinical Medicine, Guangzhou University of Chinese Medicine, Guangdong Guangzhou 510405, China;2. The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Wet Syndrome, Guangdong Guangzhou 510120, China;3. Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangdong Guangzhou 510120, China |
| |
| Abstract: | OBJECTIVE To overview the systematic reviews on the efficacy of Danhong Injection in the treatment of angina pectoris of coronary heart disease based on AMSTAR 2 and GRADE system.METHODS The CBM,CNKI,Wanfang,VIP,PubMed,The Cochrane Library,Embase and Web of Science databases were searched.Systematic reviews or Meta-analyses related to Danhong Injection in the treatment of angina pectinis of coronary heart disease ware collected.After screening and extracting,the methodological quality and evidence quality of the included studies were evaluated by using AMSTAR2 and GRADE system.RESULTS Finally,13 SRs were included.The quality evaluation of AMSTAR2 methodology including SRs ware all extremely low.The resulrs of GRADE system implied that the quality of 6 outcome indicators were "medium" evidence,17 were "low" evidence,and 26 were "extremely low" evidence.CONCLUSION The methodological quality and evidence quality of the systematic reviews of Danhong Injection in the treatment of coronary heart disease angina pectoris are low.We should strive to further carry out high-quality clinical studies and improve the methodological quality. |
| |
| Keywords: | Danhong Injection angina pectoris overview of systematic review AMSTAR2 GRADE |
|
| 点击此处可从《中国医院药学杂志》浏览原始摘要信息 |
|
点击此处可从《中国医院药学杂志》下载全文 |
|
